In vitro antimicrobial activity and therapeutic efficacy of teicoplanin in respiratory tract infections caused by gram-positive cocci

Akira Watanabe, Yoshihiro Honda, Yutaka Tokue, Satoru Shoji, Hiroshi Takahashi, Hiroaki Kikuchi, Kenji Yanase, Mikae Nakamura, Shigeo Takizawa

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    We measured in vitro antimicrobial activities of teicoplanin (TEIC), a new parenteral glycopeptide antibiotic, and evaluated its therapeutic efficacy in respiratory tract infections caused by gram-positive cocci. The minimum inhibitory concentrations (MICs) of TEIC, vancomycin (VCM), ampicillin, ceftazidime and imipenem against a total of 132 strains consisting of 7 different species, methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant 5. aureus (MRSA), Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa, were determined by the micro-broth dilution method using the Dynatech MIC 2000 system. As shown by MICs, TEIC was the most active against MSSA and MRSA. Against Enterobacteriaceae and P. aeruginosa, TEIC was ineffective, like VCM. A dose of 200 mg (4 cases) or 400 mg (2 cases) of TEIC was given daily to 6 patients for 8 to 19 days (mean : 13.8 days): three with acute pneumonia, two with secondary infection in association with old pulmonary tuberculosis and one with secondary infection in association with lung cancer. The clinical effects were excellent in three, good in two and fair in one (efficacy rate : 83.3%). Six strains were identified as causative organisms : four strains of Streptococcus pneumoniae, and one strain each of MRSA and anaerobic Streptococcus constellatus. All of them were eradicated by an administration of TEIC. Transient elevation of alkaline-phosphatase was observed in one patient, but it disappeared after the completion of therapy. From the above results, we conclude that TEIC is a useful antibiotic for parenteral use in the treatment of respiratory tract infections caused by gram-positive cocci, especially MRSA.

    Original languageEnglish
    Pages (from-to)167-172
    Number of pages6
    JournalChemotherapy
    Volume41
    DOIs
    Publication statusPublished - 1993 Jan 1

    Keywords

    • MRSA
    • Teicoplanin

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'In vitro antimicrobial activity and therapeutic efficacy of teicoplanin in respiratory tract infections caused by gram-positive cocci'. Together they form a unique fingerprint.

  • Cite this

    Watanabe, A., Honda, Y., Tokue, Y., Shoji, S., Takahashi, H., Kikuchi, H., Yanase, K., Nakamura, M., & Takizawa, S. (1993). In vitro antimicrobial activity and therapeutic efficacy of teicoplanin in respiratory tract infections caused by gram-positive cocci. Chemotherapy, 41, 167-172. https://doi.org/10.11250/chemotherapy1953.41.Supplement2_167